EP Patent

EP1559715A4 — N-2-CHLORO-4- (6,7-DIMETHOXY-4-QUINOLYL) OXY-PHENYL-N '- (5-METHYL-3-ISOXAZOLYL) UREA SALT IN CRYSTALLINE FORM

Assigned to Kyowa Kirin Co Ltd · Expires 2006-03-29 · 20y expired

What this patent protects

The present invention provides a crystal of a pharmaceutically acceptable salt of N-ä2-chloro-4-Ä(6,7-dimethoxy-4-quinolyl)oxyÜphenylü-N'-(5-m ethyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabe…

USPTO Abstract

The present invention provides a crystal of a pharmaceutically acceptable salt of N-ä2-chloro-4-Ä(6,7-dimethoxy-4-quinolyl)oxyÜphenylü-N'-(5-m ethyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.

Drugs covered by this patent

Patent Metadata

Patent number
EP1559715A4
Jurisdiction
EP
Classification
Expires
2006-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Kyowa Kirin Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.